| Literature DB >> 35120497 |
Christina M Dieli-Conwright1,2, Rebecca A Nelson3, Michael S Simon4, Melinda L Irwin5, Marian L Neuhouser6, Kerryn W Reding7, Tracy E Crane8, JoAnn E Manson9, Rami Nassir10, Aladdin H Shadyab11, Michael LaMonte11, Lihing Qi12, Cynthia A Thomson13, Candyce H Kroenke14, Kathy Pan15, Rowan T Chlebowski15, Joanne Mortimer3.
Abstract
BACKGROUND: Higher physical activity levels are associated with lower breast cancer-specific mortality. In addition, the metabolic syndrome is associated with higher breast cancer-specific mortality. Whether the physical activity association with breast cancer mortality is modified by number of metabolic syndrome components (cardiometabolic risk factors) in postmenopausal women with early-stage breast cancer remains unknown.Entities:
Keywords: Breast cancer; Metabolic syndrome; Physical activity
Mesh:
Year: 2022 PMID: 35120497 PMCID: PMC8817588 DOI: 10.1186/s12905-022-01614-3
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.809
Baseline metabolic characteristics stratified by physical activity level in 8543 participants with breast cancer in the WHI study
| Physical activity level | |||||
|---|---|---|---|---|---|
| 0 | > 0–2.9 | 3–8.9 | ≥ 9 | ||
| Age group (enrollment) | |||||
| 50 to 54 | 229 (12) | 125 (14) | 253 (13) | 490 (13) | 0.4278 |
| 55 to 59 | 440 (22) | 201 (23) | 431 (22) | 785 (21) | |
| 60 to 69 | 939 (47) | 407 (46) | 922 (47) | 1741 (47) | |
| 70 to 79 | 379 (19) | 159 (18) | 352 (18) | 690 (19) | |
| Race/ethnicity | |||||
| White | 1658 (84) | 759 (86) | 1713 (89) | 3351 (91) | < 0.0001 |
| Black | 193 (10) | 73 (8) | 119 (6) | 166 (5) | |
| Hispanic | 63 (3) | 27 (3) | 44 (2) | 63 (2) | |
| American Indian | 6 (0) | 5 (1) | 8 (0) | 11 (0) | |
| Asian/Pacific Islander | 51 (3) | 16 (2) | 50 (3) | 72 (2) | |
| Education | |||||
| High school or less | 497 (25) | 175 (20) | 345 (18) | 503 (14) | < 0.0001 |
| > High school/GED | 1474 (75) | 713 (80) | 1596 (82) | 3180 (86) | |
| CT participant | |||||
| Observational Arm | 967 (49) | 434 (49) | 1033 (53) | 2418 (65) | < 0.0001 |
| Clinical Trial Arm | 1020 (51) | 458 (51) | 925 (47) | 1288 (35) | |
| No mammogram in last 2 years | |||||
| Mammogram within 2 years | 1582 (82) | 749 (86) | 1673 (88) | 3272 (91) | |
| No mammogram within 2 years | 344 (18) | 119 (14) | 232 (12) | 343 (9) | < 0.0001 |
| Body-mass Index (BMI) kg/m2 (kg/m2) | |||||
| < 25 | 415 (21) | 234 (26) | 632 (32) | 1601 (44) | < 0.0001 |
| 25–< 30 | 640 (32) | 274 (31) | 730 (37) | 1279 (35) | |
| 30–< 35 | 478 (24) | 206 (23) | 366 (19) | 552 (15) | |
| 35 + | 440 (22) | 174 (20) | 220 (11) | 238 (6) | |
| Waist circumference | |||||
| < 88 cm | 844 (42) | 422 (47) | 1144 (58) | 2536 (68) | < 0.0001 |
| ≥ 88 cm | 1143 (58) | 470 (53) | 814 (42) | 1170 (32) | |
| History of high cholesterol | |||||
| No | 1704 (86) | 762 (85) | 1700 (87) | 3217 (87) | 0.1943 |
| Yes | 283 (14) | 130 (15) | 258 (13) | 489 (13) | |
| History of diabetes | |||||
| No | 1852 (93) | 849 (95) | 1861 (95) | 3580 (97) | < 0.0001 |
| Yes | 135 (7) | 43 (5) | 97 (5) | 126 (3) | |
| Blood pressure | |||||
| Normal | 1031 (52) | 458 (51) | 1138 (58) | 2240 (60) | < 0.0001 |
| High | 956 (48) | 434 (49) | 820 (42) | 1466 (40) | |
| Cardiometabolic abnormalities group (baseline) | |||||
| 0 | 470 (24) | 233 (26) | 669 (34) | 1494 (40) | < 0.0001 |
| 1–2 | 1348 (68) | 584 (65) | 1171 (60) | 2052 (55) | |
| 3–4 | 169 (9) | 75 (8) | 118 (6) | 160 (4) | |
| Tumor size | |||||
| < 1 cm | 564 (29) | 276 (32) | 570 (30) | 1156 (32) | 0.0096 |
| 1–< 2 cm | 794 (41) | 354 (41) | 801 (42) | 1500 (41) | |
| ≥ 2 cm | 568 (29) | 233 (27) | 537 (28) | 960 (26) | |
| Paget or diffuse | 8 (0) | 3 (0) | 5 (0) | 9 (0) | |
| Morphology—grading | |||||
| Well differentiated | 465 (25) | 244 (29) | 539 (30) | 1015 (29) | 0.0005 |
| Moderately differentiated | 847 (46) | 367 (44) | 804 (44) | 1604 (46) | |
| Poorly differentiated | 470 (26) | 206 (25) | 439 (24) | 798 (23) | |
| Anaplastic | 43 (2) | 14 (2) | 28 (2) | 55 (2) | |
| # lymph nodes examined | |||||
| Median (IQR+) | 4 (2–13) | 3 (1–11) | 4 (1–11) | 4 (1–11) | 0.0254 |
| # positive nodes | |||||
| 0 | 1322 (67) | 616 (69) | 1323 (68) | 2554 (69) | 0.0103 |
| 1–3 | 322 (16) | 140 (16) | 320 (16) | 551 (15) | |
| ≥ 4 | 135 (7) | 44 (5) | 105 (5) | 181 (5) | |
| + nodes NOS | 6 (0) | 4 (0) | 9 (0) | 2 (0) | |
| None examined | 200 (10) | 88 (10) | 201 (10) | 413 (11) | |
| Summary stage (SEER) | |||||
| Localized | 1482 (75) | 691 (77) | 1494 (76) | 2895 (78) | 0.0053 |
| Regional | 505 (25) | 201 (23) | 464 (24) | 811 (22) | |
| Hormone receptor status | |||||
| ER or PR+ | 1614 (86) | 748 (88) | 1632 (87) | 3073 (88) | 0.2144 |
| ER and PR− | 257 (14) | 103 (12) | 252 (13) | 432 (12) | |
| HER2/NEU | |||||
| Positive | 259 (17) | 87 (12) | 215 (14) | 402 (14) | 0.0504 |
| Negative | 1298 (83) | 625 (88) | 1357 (86) | 2478 (86) | |
| Smoking status | |||||
| Never smoker | 964 (49) | 471 (53) | 1007 (52) | 1709 (47) | < 0.0001 |
| Past smoker | 826 (42) | 354 (40) | 824 (42) | 1794 (49) | |
| Current smoker | 171 (9) | 58 (7) | 108 (6) | 169 (5) | |
| Alcohol intake | |||||
| Non drinker | 253 (13) | 106 (12) | 191 (10) | 239 (6) | < 0.0001 |
| Past drinker | 413 (21) | 171 (19) | 288 (15) | 505 (14) | |
| < 1 drink per month | 295 (15) | 110 (12) | 249 (13) | 385 (10) | |
| < 1 drink per week | 400 (20) | 179 (20) | 419 (21) | 763 (21) | |
| 1 to < 7 drinks per week | 409 (21) | 217 (24) | 557 (29) | 1160 (31) | |
| 7 + drinks per week | 200 (10) | 107 (12) | 247 (13) | 638 (17) | |
| Cause of death | |||||
| Alive | 1219 (62) | 586 (67) | 1383 (72) | 2600 (71) | < 0.0001 |
| Breast cancer | 190 (10) | 75 (9) | 156 (8) | 259 (7) | |
| CVD | 192 (10) | 70 (8) | 122 (6) | 269 (7) | |
| Other cancer | 121 (6) | 42 (5) | 93 (5) | 189 (5) | |
| Alzheimer’s/Dementia | 51 (3) | 23 (3) | 61 (3) | 98 (3) | |
| Other | 178 (9) | 74 (9) | 110 (6) | 233 (6) | |
Association between quartiles of activity level and mortality risk in 8543 participants with breast cancer in the WHI study
| # of participants | Physical activity level group | Ptrend | HR (95% CI) | PInteractionc | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | > 0–2.9 | 3–8.9 | ≥ 9 | |||||
| All | # Deaths | 768 | 306 | 575 | 1106 | |||
| HR (95% CI) | 1.00 | 0.96 (0.84–1.10) | 0.80 (0.72–0.90) | 0.86 (0.78–0.95) | < 0.001 | 0.95 (0.92–0.98) | ||
| # of metabolic risk factors | ||||||||
| 0 | HR (95% CI) | 1.00 | 0.98 (0.71–1.36) | 0.83 (0.65–1.07) | 0.84 (0.67–1.05) | 0.09 | 0.94 (0.88–1.01) | 0.75 |
| 1–2 | HR (95% CI) | 1.00 | 0.96 (0.82–1.13) | 0.76 (0.66–0.87) | 0.84 (0.75–0.95) | 0.001 | 0.94 (0.90–0.97) | |
| 3–4 | HR (95% CI) | 1.00 | 1.10 (0.73–1.66) | 0.87 (0.61–1.26) | 0.91 (0.65–1.28) | 0.48 | 0.96 (0.86–1.07) | |
| All | # Deaths | 190 | 75 | 156 | 259 | |||
| HR (95% CI) | 1.00 | 1.00 (0.76–1.31) | 0.92 (0.74–1.15) | 0.85 (0.70–1.04) | 0.09 | 0.95 (0.89–1.01) | ||
| # Of metabolic risk factors | ||||||||
| 0 | HR (95% CI) | 1.00 | 1.16 (0.64–2.09) | 0.85 (0.54–1.34) | 0.92 (0.62–1.37) | 0.54 | 0.96 (0.85–1.09) | 0.46 |
| 1–2 | HR (95% CI) | 1.00 | 0.86 (0.61–1.20) | 0.85 (0.65–1.11) | 0.77 (0.60–0.99) | 0.04 | 0.92 (0.85–1.00) | |
| 3–4 | HR (95% CI) | 1.00 | 2.71 (0.85–8.64) | 0.82 (0.28–2.38) | 1.18 (0.45–3.11) | 0.87 | 0.97 (0.72–1.32) | |
Median follow-up since enrollment was 19 years, median follow-up since breast cancer diagnosis was 9.5 years
aThe all cause multivariate model adjusts for age group, race/ethnicity alcohol intake, smoking status, BMI kg/m2, # of metabolic risk factors, hormone receptor status, grade, HER2/NEU number of examined lymph nodes, number of positive lymph nodes, tumor size, and stage
bThe breast cancer multivariate model adjusts for age group, alcohol intake, # of metabolic risk factors, hormone receptor status, grade, # positive lymph nodes, tumor size, and stage
cPInteraction was calculated with the cross-product between physical activity level, and # of metabolic risk factors the separate multivariate Cox proportional hazards model